Sebag-Montefiore et al., ASCO 2006 @ 3y Preop. RT + OP (n=674) OP + RCT in CRM + (n=676) Hazard- Ratio (95%CI) Local recurence 4.7% 11.1% 2.5 (1.61-3.79) Disease free survival 79.5% 74.9% 1.31 (1.02-1.67) Overall survival 80.8% 78.7% 1.25 (0.98-1.59) MRC CR07: 5x5 TME vs. TME RCT in CRM+
9
Embed
Sebag-Montefiore et al., ASCO 2006 @ 3y Preop. RT + OP (n=674) OP + RCT in CRM + (n=676) Hazard- Ratio (95%CI) Local recurence4.7%11.1% 2.5 (1.61-3.79)
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Sebag-Montefiore et al., ASCO 2006
@ 3yPreop. RT
+ OP(n=674)
OP + RCT in CRM +(n=676)
Hazard-Ratio
(95%CI)
Local recurence 4.7% 11.1%2.5
(1.61-3.79)
Disease free survival
79.5% 74.9%1.31
(1.02-1.67)
Overall survival 80.8% 78.7%1.25
(0.98-1.59)
MRC CR07: 5x5 TME vs. TME RCT in CRM+
CAO/ARO/AIO-94
TMETME
TMETME
RR
Sauer et al. N Eng J Med 2004
823 patients
Primary endpoint: overall survival
(4 cycles)
(4 cycles)
Local recurrence rate
FFCD 9203
SS
SS
RR(4 Zyklen)
(4 Zyklen)
Gerard et al. J Clin Oncol 2006, ASCO 2005
Primary endpoint: overall survival
733 patients
TME not routine
Local recurrence rate
EORTC 22921
Bosset et al. N Eng J Med 2006Primary endpoint: overall survival